[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

EA201170899A1 - Производные 2-пиридин-2-ил-пиразол-3(2h)-она, их получение и применение в терапии в качестве активаторов hif - Google Patents

Производные 2-пиридин-2-ил-пиразол-3(2h)-она, их получение и применение в терапии в качестве активаторов hif

Info

Publication number
EA201170899A1
EA201170899A1 EA201170899A EA201170899A EA201170899A1 EA 201170899 A1 EA201170899 A1 EA 201170899A1 EA 201170899 A EA201170899 A EA 201170899A EA 201170899 A EA201170899 A EA 201170899A EA 201170899 A1 EA201170899 A1 EA 201170899A1
Authority
EA
Eurasian Patent Office
Prior art keywords
alkyl
therapy
aryl
heterocycloalkyl
pyrazol
Prior art date
Application number
EA201170899A
Other languages
English (en)
Other versions
EA019591B1 (ru
Inventor
Жан-Мишель Альтенбюрже
Валери Фоссе
Стефан Иллиано
Жеральдин Манетт
Original Assignee
Санофи
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR0807474A external-priority patent/FR2940651B1/fr
Priority claimed from FR0904092A external-priority patent/FR2949466A1/fr
Application filed by Санофи filed Critical Санофи
Publication of EA201170899A1 publication Critical patent/EA201170899A1/ru
Publication of EA019591B1 publication Critical patent/EA019591B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6875—Nucleoproteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Vascular Medicine (AREA)

Abstract

Изобретение относится к соединениям, соответствующим формуле (I), в которой: R представляет собой -SO-NR3R4, атом водорода, атом галогена, -галоген(С-С)алкил, -COR5 или SOR4; R1 представляет собой гетероциклоалкил, не содержащий атом азота, -W-(C-C)циклоалкил, -W-арил, -W-гетероарил, -W-гетероциклоалкил, -W-COOR5, -W-CONR5R6; R2 представляет собой атом водорода, -(С-С)алкил, -(С-С)алкилен-О-(С-С)алкил, -галоген(С-С)алкил, -W-COOR5, -W-C(О)NHR5 или -W-C(О)NR5R6; n равно 0, 1 или 2; W означает -(С-С)алкилен- или -(C-C)циклоалкилен-; R3 и R4, являющиеся одинаковыми или разными, независимо друг от друга представляют собой такие группы, как атом водорода, -(С-С)алкил, -(C-C)циклоалкил, -(С-С)алкилен-О-(С-С)алкил, арил, -СН-арил, гетероарил, гетероциклоалкил, -W-OH, -W-CHOH-CHOH, -W-COR5, -W-NR5R6 или -W-О-(CH)-арил; или R3 и R4 совместно с атомом азота, с которым они связаны, образуют гетероциклоалкил; R5 и R6, являющиеся одинаковыми или разными, независимо друг от друга представляют собой атомы водорода, -(С-С)алкилы или (С-С)галогеналкилы; изобретение относится также к способу их получения и их применению в терапии.
EA201170899A 2008-12-29 2009-12-24 Производные 2-пиридин-2-ил-пиразол-3(2h)-она, их получение и применение в терапии в качестве активаторов hif EA019591B1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR0807474A FR2940651B1 (fr) 2008-12-29 2008-12-29 Derives de 2-pyridin-2-yl-pyrazol-3(2h)-one,leur preparation et leur application en therapeutique comme activateurs de hif
FR0904092A FR2949466A1 (fr) 2009-08-28 2009-08-28 Derives de 2-pyridin-2-yl-pyrazol-3(2h)-one, leur preparation et leur application en therapeutique comme activateurs de hif
PCT/FR2009/052691 WO2010076524A2 (fr) 2008-12-29 2009-12-24 Derives de 2-pyridin-2-yl-pyrazol-3(2h)-one, leur preparation et leur application en therapeutique comme activateurs de hif

Publications (2)

Publication Number Publication Date
EA201170899A1 true EA201170899A1 (ru) 2012-02-28
EA019591B1 EA019591B1 (ru) 2014-04-30

Family

ID=42008610

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201170899A EA019591B1 (ru) 2008-12-29 2009-12-24 Производные 2-пиридин-2-ил-пиразол-3(2h)-она, их получение и применение в терапии в качестве активаторов hif

Country Status (35)

Country Link
US (1) US8541455B2 (ru)
EP (1) EP2382205B1 (ru)
JP (1) JP5734870B2 (ru)
KR (1) KR20110099786A (ru)
CN (1) CN102333769B (ru)
AR (1) AR074915A1 (ru)
AU (1) AU2009334569B2 (ru)
BR (1) BRPI0924060A8 (ru)
CA (1) CA2748411A1 (ru)
CL (1) CL2011001496A1 (ru)
CO (1) CO6400141A2 (ru)
CR (1) CR20110361A (ru)
CY (1) CY1115368T1 (ru)
DK (1) DK2382205T3 (ru)
EA (1) EA019591B1 (ru)
EC (1) ECSP11011155A (ru)
ES (1) ES2481042T3 (ru)
HR (1) HRP20140680T1 (ru)
IL (1) IL213789A (ru)
MA (1) MA32976B1 (ru)
MX (1) MX2011007054A (ru)
MY (1) MY179093A (ru)
NZ (1) NZ593751A (ru)
PA (1) PA8856201A1 (ru)
PE (1) PE20120416A1 (ru)
PL (1) PL2382205T3 (ru)
PT (1) PT2382205E (ru)
SG (1) SG172803A1 (ru)
SI (1) SI2382205T1 (ru)
SM (1) SMT201400097B (ru)
TN (1) TN2011000267A1 (ru)
TW (1) TWI482763B (ru)
UY (1) UY32369A (ru)
WO (1) WO2010076524A2 (ru)
ZA (1) ZA201104783B (ru)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY155244A (en) 2008-12-29 2015-09-30 Sanofi Sa Derivatives of 2-pyridin-2-yl-pyrazol-3(2h)-one, preparation and therapeutic use thereof
WO2012133783A1 (ja) * 2011-03-31 2012-10-04 キッセイ薬品工業株式会社 ベンジルピラゾール誘導体の製造方法およびその製造中間体
CA2869130A1 (en) 2012-03-30 2013-10-03 Daiichi Sankyo Company, Limited 4-alkanoylamino-3-pyrazolone derivatives
MY184218A (en) * 2013-03-29 2021-03-26 Takeda Pharmaceuticals Co 6-(5-hydroxy-1h-pyrazol-1-yl)nicotinamide derivatives and their use as phd inhibitors
DE102016223133A1 (de) 2016-11-23 2018-05-24 Deere & Company Geschwindigkeitskontrolle einer Erntemaschine

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4023488A1 (de) * 1990-07-24 1992-01-30 Bayer Ag 1-(pyri(mi)dyl-(2)) -5-hydroxy-pyrazol-mikrobizide
US5750088A (en) 1993-03-30 1998-05-12 The Dupont Merck Pharmaceutical Company Stable hydrazones linked to a peptide moiety as reagents for the preparation of radiopharmaceuticals
CA2530679A1 (en) 2003-06-30 2005-04-07 Hif Bio, Inc. Compounds for treating angiogenesis
DE102005019712A1 (de) * 2005-04-28 2006-11-09 Bayer Healthcare Ag Dipyridyl-dihydropyrazolone und ihre Verwendung
PE20071020A1 (es) 2006-03-07 2007-12-11 Smithkline Beecham Corp Compuestos derivados de glicina n-sustituidos como inhibidores de prolil hidroxilasa
WO2008047198A1 (en) 2006-10-16 2008-04-24 Pfizer Products Inc. Therapeutic pyrazolyl thienopyridines
DE102006050516A1 (de) 2006-10-26 2008-04-30 Bayer Healthcare Ag Substituierte Dihydropyrazolone und ihre Verwendung
BRPI0812361A2 (pt) 2007-05-18 2015-02-03 Bayer Schering Pharma Ag Derivados de pirazol heteroaril-substituídos úteis parao tratamento de distúrbios e doenças hiperproliferativos associados à angiogênese

Also Published As

Publication number Publication date
TWI482763B (zh) 2015-05-01
WO2010076524A2 (fr) 2010-07-08
EP2382205A2 (fr) 2011-11-02
JP5734870B2 (ja) 2015-06-17
TW201028391A (en) 2010-08-01
NZ593751A (en) 2013-08-30
BRPI0924060A2 (pt) 2015-07-07
BRPI0924060A8 (pt) 2015-09-29
IL213789A0 (en) 2011-07-31
CO6400141A2 (es) 2012-03-15
PA8856201A1 (es) 2010-07-27
IL213789A (en) 2014-11-30
TN2011000267A1 (fr) 2012-12-17
MA32976B1 (fr) 2012-01-02
US8541455B2 (en) 2013-09-24
WO2010076524A3 (fr) 2010-08-26
PL2382205T3 (pl) 2014-09-30
US20110294788A1 (en) 2011-12-01
ZA201104783B (en) 2012-09-26
JP2012513976A (ja) 2012-06-21
SMT201400097B (it) 2014-09-08
ECSP11011155A (es) 2011-07-29
PE20120416A1 (es) 2012-05-08
MX2011007054A (es) 2011-11-29
SG172803A1 (en) 2011-08-29
HRP20140680T1 (hr) 2014-10-10
CL2011001496A1 (es) 2011-10-28
CN102333769B (zh) 2014-08-27
AU2009334569B2 (en) 2016-02-25
UY32369A (es) 2010-07-30
PT2382205E (pt) 2014-07-28
AR074915A1 (es) 2011-02-23
AU2009334569A1 (en) 2011-07-21
MY179093A (en) 2020-10-27
CR20110361A (es) 2011-09-20
CA2748411A1 (fr) 2010-07-08
CN102333769A (zh) 2012-01-25
SI2382205T1 (sl) 2014-08-29
DK2382205T3 (da) 2014-07-28
EP2382205B1 (fr) 2014-04-23
KR20110099786A (ko) 2011-09-08
EA019591B1 (ru) 2014-04-30
CY1115368T1 (el) 2017-01-04
ES2481042T3 (es) 2014-07-29

Similar Documents

Publication Publication Date Title
CO6300865A2 (es) Derivados polisustituidos de 2 aril-6-fenil-imidazo[1,2-a]piridinas su preparacion y su aplicacion en terapeutica
EA200970311A1 (ru) ПРОИЗВОДНЫЕ 2-АРИЛ-6-ФЕНИЛИМИДАЗО[1,2-α]ПИРИДИНОВ, ИХ ПОЛУЧЕНИЕ И ПРИМЕНЕНИЕ В ТЕРАПИИ
MX2010003445A (es) Derivados de nicotinamida, su preparacion y su uso terapeutico.
EA201171328A1 (ru) Производное замещенного изохинолина
DK1583524T3 (da) Bis(thiohydrazidamid)-forbindelser til behandling af multilægemiddel-resistent cancer
EA201170899A1 (ru) Производные 2-пиридин-2-ил-пиразол-3(2h)-она, их получение и применение в терапии в качестве активаторов hif
NO20076006L (no) Acetylenderivater
EA201071112A1 (ru) ПРОИЗВОДНЫЕ ПОЛИЗАМЕЩЁННЫХ 2-АРИЛ-6-ФЕНИЛИМИДАЗО[1,2-a]ПИРИДИНОВ, СПОСОБ ИХ ПОЛУЧЕНИЯ И ПРИМЕНЕНИЕ ИХ В ТЕРАПИИ
TW200602461A (en) Dibenzofuran, dibenzothiophene and fluorene derivatives
EA200870192A1 (ru) Новые серосодержащие производные циклической мочевины, их получение и их фармацевтическое применение в качестве ингибиторов киназ
ECSP077422A (es) Derivado de bencimidazol ariloxi-sustituido
WO2010089510A3 (fr) Dérivés d'azaspiranyl-alkylcarbamates d'hétérocycles à 5 chaînons, leur préparation et leur application en thérapeutique
MY148653A (en) N, n-substituted 3-aminopyrrolidine compounds useful as monoamines reuptake inhibitors
WO2006136837A3 (en) Pharmaceutical combinations comprising pyrazole derivatives as protein kinase modulators
CY1112679T1 (el) Κινολινες και θεραπευτικη χρηση αυτων
ATE510820T1 (de) Alkoxy-polyester-verbindungen, zusammensetzungen und verwendungsverfahren dafür
EA201071012A1 (ru) Производные азетидинов, способ их получения и применение их в терапии
ATE381554T1 (de) Aroylfurane und aroylthiophene, die sich für die behandlung von krebs eignen
MY155244A (en) Derivatives of 2-pyridin-2-yl-pyrazol-3(2h)-one, preparation and therapeutic use thereof
PE20050336A1 (es) Compuestos triciclicos como inhibidores de la proteina farnesil transferasa
TW200708506A (en) Derivatives of triazines, their preparation and their application in therapeutics
NO20085308L (no) Dualmolekyler inneholdende et peroksidderivat, deres syntese og deres terapautiske anvendelser
NO20076161L (no) Fremgangsmater for fremstilling av 4-bifenylazetidin-2-oner
EA201390323A1 (ru) Производные 4-(метиламинофенокси)пиридин-3-илбензамида для лечения рака
EA201390170A1 (ru) Составы

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): RU